Rohtak becomes new Covid hotspot tribuneindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribuneindia.com Daily Mail and Mail on Sunday newspapers.
The pandemic has entered yet another phase, with the Omicron variant wreaking havoc across the globe. The high infection rate of this new cause for concern, in India, has also triggered a ‘war of medical opinions’ between the Indian Council of Medical Research (ICMR) and the Drugs Controller General of India (DCGI). Pharma majors are churning out viable treatment options at a feverish pace, in a bid to become the most widely accepted drug listed in COVID-19 treatment protocols. Merck’s Molnupiravir is one such drug that is embroiled in a ‘safety vs efficacy’ contest. Let’s investigate further.
"We believe a ‘plug and play’ model of supervised home-based care can easily be adopted by communities to assist those who are medically able to recover at home," said Renjen.
Molnupiravir best bet in fight against Covid: Experts - INDIA New England News indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.
Molnupiravir inhibits the replication of certain RNA viruses. It is basically to be used in treating Covid-19 infected people of more than 50 years of age and in those with multiple comorbidities. The recommended dose of Molnupiravir 800 mg is twice a day for five days.